Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från iCoat Medical via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Språk
Typ
Språk
Typ
2023-11-09 17:55:00
Kallelse till aktieägarmöte i iCoat Medical AB den 7 december 2023
Bästa aktieägare i iCoat Medical AB, 2023 har varit ett intensivt år för iCoat Medical där vi fortsatt den kliniska utvecklingen av vårt prioriterade projekt inom njurtransplantation samt arbetat vidare med de prekliniska indikationerna hjärttransplantation och öppen hjärtkirurgi.I september tog vi ett betydande steg framåt i vår kliniska utveckling när vi meddelade positiva resultat f...
2023-08-15 08:00:00
ICOAT MEDICAL PUBLISHES INTERIM REPORT Q2 2023
Press release Stockholm, 15 August 2023
2023-05-16 08:00:00
ICOAT MEDICAL PUBLISHES INTERIM REPORT Q1 2023
Press release Stockholm, 16 May 2023
2023-05-10 17:35:00
iCoat Medical completes enrollment in First In Human study of TUM012 in kidney transplantation
All 18 of the intended patients have been successfully included into iCoat Medical’s First-in-Human trial ATMIReSo far no serious or relevant adverse events linked to the Investigational Medicinal Product (IMP) have been observedTUM012 is the first drug being developed for kidney transplantations based on iCoat Medical's patented coating technology platformTopline data from ATMIRe is expected in...
2023-04-20 16:30:00
COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) ANNUAL GENERAL MEETING 20 APRIL 2023
The annual general meeting in iCoat Medical AB (publ), corp. reg. no 559172-8208 (the “Company”) was held on 20 April 2023 in Stockholm whereby the shareholders primarily resolved on the following matters
2023-04-05 18:45:00
Carl Bjartmar appointed Chief Commercial Officer of iCoat Medical
Lund, Sweden, 5 April 2023
2023-03-24 10:00:00
iCoat Medical publishes Annual Report 2022
iCoat Medical today publishes its Annual Report for the financial year 2022. The Annual Report is attached to this press release and available on the company's website www.icoatmedical.com The Annual Report is only available in Swedish. For additional information, please contact:Peder Waern, CEO – iCoat Medical ABE-mail: peder.waern@icoatmedical.comMattias Springare, CFO – iCoat Medical ABE-ma...
2023-03-23 18:40:00
NOTICE OF ANNUAL GENERAL MEETING IN ICOAT MEDICAL AB (PUBL)
The shareholders in iCoat Medical AB (publ), corporate registration number 559172‑8208 (the “Company”) are hereby convened to the Annual general meeting on Thursday 20 April 2023 at 2.00 p.m. at the Company’s premises at WeWork, floor 6, Malmskillnadsgatan 32, 111 51 Stockholm
2023-03-22 18:00:00
ICOAT MEDICAL EXPANDS ITS PATENT PORTFOLIO
Two co-founders and one advisor to iCoat Medical have made a new invention linked to iCoat Medical’s focus area ischemia reperfusion injury.The invention is centered around a new use of PEG-phospholipid molecules and the International application was filed in March.The invention and connected IP is expected to continue iCoat Medical’s pioneering research and development within ischemia reperfu...
2023-02-15 12:00:00
ICOAT MEDICAL PUBLISHES INTERIM REPORT Q4 2022
Press release Stockholm, 15 February 2023
2022-12-17 10:28:00
COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) EXTRAORDINARY GENERAL MEETING 16 DECEMBER 2022
The extra general meeting in iCoat Medical AB (publ), corp. reg. no 559172-8208 (the “Company”) was held on 16 December 2022 in Stockholm whereby the shareholders primarily resolved on the following matters
2022-11-25 10:45:00
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ICOAT MEDICAL AB (PUBL)
The shareholders in iCoat Medical AB (publ), corporate registration number 559172-8208 (the “Company”) are hereby convened to the extraordinary general meeting to be held on Friday, December 16, 2022 at 12 am at the Company’s premises at WeWork, floor 6, Malmskillnadsgatan 32, 111 51 Stockholm
2022-11-15 08:00:00
iCoat Medical publishes Interim Report Q3 2022
Press release Stockholm, 15 November 2022
2022-10-19 17:00:00
The U.S. Food and Drug Administration has granted iCoat Medical Orphan Drug Designation for TUM012 in the United States
Today, iCoat Medical announces that the U.S. Food and Drug Administration has issued a positive decision on the company’s application for Orphan Drug Designation of TUM012 for solid organ transplantation in the United States
2022-10-11 13:00:00
ICOAT MEDICAL ANNOUNCES SECOND INTERIMDATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012
Malmö, October 11th, 2022 – iCoat Medical AB (publ.) (“iCoat”), a clinical-stage pharmaceutical company developing novel therapeutics targeting the innate immune system, today announces that more than 50% of the intended patients in the ongoing First-in-Human trial with the novel drug TUM012 have been treated without complications linked to the IMP. The trial is expected to be completed dur...
2022-08-25 08:00:00
iCoat Medical publishes Interim Report Q2 2022
Today iCoat Medical releases the company´s first public interim report for the period january-june 2022
2022-08-10 14:52:00
ICOAT MEDICAL ANNOUNCES INTERIM DATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012
Malmö, August 10th, 2022 – iCoat Medical AB (publ.), a clinical-stage pharmaceutical company developing novel therapeutics targeting the innate immune system, today announces that the first four patients included in a sentinel fashion into the ongoing First-in-Human trial ATMIRe, with the novel drug TUM012, have been treated without complications. The trial is expected to be completed during H1...
2022-06-16 14:00:00
COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) ANNUAL GENERAL MEETING 15 JUNE 2022
An annual general meeting (“AGM”) in iCoat Medical AB (publ), corp. reg. no 559172-8208 (the “Company”) was held on 15 June 2022 in Stockholm. All decisions were made in accordance with the proposals presented in the notice of the AGM
2022-06-13 17:00:00
iCoat Medical to present at the 14th International Conference on Complement Therapeutics in Rhodes, Greece in June 2022
iCoat Medical has been given the opportunity to present its preclinical data of TUM012 at the 14th International Conference on Complement Therapeutics in Rhodes, Greece in June 2022
2022-06-04 13:31:00
iCoat Medical to present at the 29th International Congress of The Transplantation Society in Buenos Aires, Argentina in September 2022
iCoat Medical has been given the opportunity to present our research at the 29th International Congress of The Transplantation Society to be held in Buenos Aires in September 2022
2022-05-20 12:23:00
NOTICE OF ANNUAL GENERAL MEETING IN ICOAT MEDICAL AB (PUBL)
The shareholders in iCoat Medical AB (publ), corporate registration number 559172-8208 (the “Company”) are hereby convened to the Annual Meneral meeting on Wednesday, June 15, 2022 at 13.30 at the Company’s premises at WeWork, floor 6, Malmskillnadsgatan 32, 111 51 Stockholm
2022-05-16 11:43:00
iCoat Medical publishes Annual Report 2021
iCoat Medical publishes Annual Report 2021
2022-05-09 17:21:00
Göran Lerenius joins iCoat Medical as General Counsel
Today, iCoat Medical welcomes Göran Lerenius as its General Counsel
2022-04-25 12:17:00
iCoat Medical’s Chief Medical Officer Alireza Biglarnia featured in article from Njurfonden
On April 19th, Njurfonden published an interview with iCoat Medical’s Chief Medical Officer Alireza Biglarnia highlighting his research and iCoat Medical’s ongoing First In Human-trial
2022-04-21 18:45:00
The European Commission has granted iCoat Medical Orphan Drug Designation for TUM012 in the EU
Today, iCoat Medical announces that the European Commission has issued a positive decision on the company’s application for Orphan Drug Designation of TUM012 for organ transplantation
2022-03-25 08:50:00
Jacob Westman joins iCoat Medical as Head of CMC
Today, iCoat Medical welcomes Jacob Westman as its Head of Chemistry, Manufacturing and Controls on a consultancy basis.iCoat Medical has a growing pipeline of indications as well as an ambitious clinical program outlined for the coming years. The company aim to not only expand its clinical program for TUM012 but also advance its second product family TUM020 towards clinical stage. As part of this...